Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial

American Journal of Cardiology

Volumn 93, Issue 7, 2004, Pages 843-847

  Servoss, Stephen J ^b   Wan, Ying ^b   Snapinn, Steven M ^b   DiBattiste, Peter M ^b   Zhao, Xue Qiao ^b   Theroux, Pierre ^b   Jang, Ik Kyung ^b   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; TIROFIBAN;

ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; TREATMENT OUTCOME;

ACUTE DISEASE; ANGINA PECTORIS; CORONARY ARTERY BYPASS; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME; TREATMENT OUTCOME; TYROSINE;

EID: 1842582293     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.12.021     Document Type: Article

References (14)

1. Labinaz M., Kilaru R., Pieper K., Marso S.P., Kitt M.M., Simoons M.L., Califf R.M., Topol E.J., Armstrong P.W., Harrington R.A. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting results from the Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation. 105:2002;322-327.
2. Roffi M., Mukherjee D., Chew D.P., Bhatt D.L., Cho L., Robbins M.A., Ziada K.M., Brennan D.M., Ellis S.G., Topol E.J. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts a pooled analysis of five randomized clinical trials. Circulation. 106:2002;3063-3067.
3. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
4. Zhao X.Q., Theroux P., Snapinn S.M., Sax F.L. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms). PRISM-PLUS Investigators. Circulation. 100:1999;1609-1615.
5. Chesebro J.H., Knatterud G., Roberts R., Borer J., Cohen L.S., Dalen J., Dodge H.T., Francis C.K., Hillis D., Ludbrook P. Thrombolysis In Myocardial Infarction (TIMI) Trial, phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 76:1987;142-154.
6. Antman E.M., Cohen M., Bernink P.J., McCabe C.H., Horacek T., Papuchis G., Mautner B., Corbalan R., Radley D., Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI a method for prognostication and therapeutic decision making. JAMA. 284:2000;835-842.
7. Sabatine M.S., Januzzi J.L., Snapinn S., Theroux P., Jang I.K. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol. 88:2001;488-492.
8. Waters D.D., Walling A., Roy D., Theroux P. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. Am J Cardiol. 58:1986;465-469.
9. Wiseman A., Waters D.D., Walling A., Pelletier G.B., Roy D., Theroux P. Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. J Am Coll Cardiol. 12:1988;873-880.
10. Kleiman N.S., Anderson H.V., Rogers W.J., Theroux P., Thompson B., Stone P.H. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis In Myocardial Ischemia III Registry). Am J Cardiol. 77:1996;227-231.
11. Labinaz M., Sketch M.H. Jr., Ellis S.G., Abramowitz B.M., Stebbins A.L., Pieper K.S., Holmes D.R. Jr., Califf R.M., Topol E.J. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. Am Heart J. 141:2001;469-477.
12. Januzzi J.L., Chae C.U., Sabatine M.S., Jang I.K. Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis. 11:2001;211-215.
13. Theroux P., Alexander J. Jr., Pharand C., Barr E., Snapinn S., Ghannam A.F., Sax F.L. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 102:2000;2466-2472.
14. Baim D.S., Wahr D., George B., Leon M.B., Greenberg J., Cutlip D.E., Kaya U., Popma J.J., Ho K.K., Kuntz R.E. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 105:2002;1285-1290.